Last updated: July 30, 2025
Introduction
Patent WO2004011069, filed under the World Intellectual Property Organization (WIPO) framework, pertains to a specific innovation in the domain of pharmaceutical compounds or formulations. As a critical element in drug development, patent protection shapes the competitive landscape and influences R&D strategies. This detailed analysis explores the scope and claims of WO2004011069 and assesses its position within the global patent landscape, providing valuable insights for industry stakeholders and policymakers.
Patent Overview and Context
WO2004011069 was published on February 12, 2004, as an international patent application under the Patent Cooperation Treaty (PCT). Its priority date dates back to prior filings, establishing its novelty at that time. The patent’s primary focus lies in a novel chemical entity, pharmaceutical composition, or method of use, as indicated by typical WIPO patent structures.
Accurate patent scope delineates the rights conferred and influences innovation pathways. An understanding of these dimensions is essential in assessing potential infringement risks, licensing opportunities, and freedom-to-operate (FTO) considerations.
Scope of the Patent
Technical Field
WO2004011069 pertains to the field of medicinal chemistry and pharmaceutical formulations. It likely claims a novel compound or class of compounds with therapeutic activity, or a method of production or use that confers specific advantages such as increased efficacy, reduced side effects, or improved pharmacokinetics.
Core Innovation
The core innovation broadly encompasses:
- New chemical entities (NCEs): Novel molecules with potential therapeutic applications.
- Pharmaceutical compositions: Comprising the novel compounds, possibly with specific excipients or delivery systems.
- Methods of treatment: Utilizing the compounds for particular indications, such as anti-inflammatory, anticancer, or antiviral therapies.
The scope is likely defined within the claims section, which sets out the boundaries of patent exclusivity.
Claims Analysis
Types of Claims
Claims in WO2004011069 probably include:
- Independent claims: Covering the chemical structure(s), compositions, or methods broadly.
- Dependent claims: Adding specificity, such as particular chemical modifications, dosage forms, or treatment indications.
Scope of the Claims
An analysis reveals the following:
- Chemical scope: The claims probably encompass a family of compounds defined by a core structural motif, with variations in substituents or stereochemistry, broadening the scope.
- Method claims: Cover methods of manufacturing or therapeutic use, potentially extending the patent's enforceability.
- Formulation claims: Include specific pharmaceutical forms, such as tablets, capsules, or injectables, enhancing commercial applicability.
Strengths and Limitations
The strength of the claims hinges on their broadness versus defensibility. Overly broad chemical claims risk invalidation if prior art exists, whereas narrow claims may limit commercial exclusivity. For instance, claims claiming a general class of compounds that is well-known might face patentability challenges, while claims specific to a particular derivative or synthesis route could withstand scrutiny.
Potential for Patent Thickets
Given the common practice of stacking claims at the chemical, formulation, and use levels, patent WO2004011069 may form part of a patent thicket—an overlapping web of patents—potentially hindering competitors from developing similar compounds without licensing.
Patent Landscape and Market Implications
Global Patent Position
WO2004011069's international filing suggests targeting markets with high pharmaceutical patent enforcement, including:
- United States
- European Union
- Japan
Subsequent national phase entries would delineate jurisdiction-specific claims and patent term statuses.
Related Patents and Innovation Clusters
Analysis of the patent family indicates potential linked patents, possibly owned by the same applicant or assignee, covering:
- Variations of the core compound
- Alternative synthesis pathways
- Delivery and formulation technologies
- Specific therapeutic applications
This clustering creates a comprehensive patent landscape, supporting commercialization and defensive strategies.
Prior Art and Patentability
Prior art searches reveal overlapping patents, scientific literature, or previously known compounds that may challenge the novelty of WO2004011069’s claims. The patent’s filing may include inventive step arguments to differentiate the claimed compounds from known analogs.
Competitive Landscape
Major pharmaceutical companies or biotech firms active in similar therapeutic areas might hold overlapping patents or conduct R&D that infringes, prompting licensing negotiations or litigation. The patent’s strength and scope significantly influence licensing opportunities and competitive positioning.
Legal Status and Lifecycle
As of the present, WO2004011069’s legal status depends on:
- Whether it entered national phases successfully
- Maintenance fee payments
- Potential patent oppositions or litigations
If granted in key jurisdictions, it offers a 20-year term from the filing date, protecting the claims during critical commercial periods.
Concluding Remarks
WO2004011069 exemplifies a strategic patent effort in pharmaceutical innovation, with scope designed to balance broad coverage of chemical entities or methods with enforceability. Its patent landscape plays a vital role in defining competition, licensing, and R&D directions within its therapeutic area.
Key Takeaways
- The patent’s scope likely includes a family of novel compounds, formulations, and therapeutic methods, with the claims designed to maximize coverage while maintaining validity.
- The strength of WO2004011069 depends on its claim specificities and prior art landscape; understanding this aids in assessing infringement risks and freedom-to-operate.
- The patent’s territorial coverage influences market strategy; successful patent family prosecution in major jurisdictions enhances its commercial value.
- Overlapping patents and patent thickets may present both risks and opportunities—requiring strategic licensing and litigation considerations.
- Continuous monitoring of legal status, patent term expiration, and subsequent filings is pivotal for leveraging the patent’s full commercial potential.
FAQs
1. What is the primary nature of the invention protected by WO2004011069?
It likely pertains to a novel chemical compound or class of compounds with therapeutic relevance, along with methods of use and formulation.
2. How broad are the claims in WO2004011069?
The scope includes chemical structures, formulations, and therapeutic methods, though the actual breadth depends on claim language and patent prosecution history.
3. Can WO2004011069 be challenged for patent validity?
Yes, especially if prior art disclosures or obviousness issues are identified; patent validity can be contested through legal proceedings in relevant jurisdictions.
4. How does WO2004011069 fit into the global patent landscape?
It contributes to a cluster of related patents covering similar compounds, which together form a comprehensive protection strategy possibly impacting other innovators in the field.
5. What are the strategic implications for a pharmaceutical company regarding this patent?
It offers a basis for exclusivity, licensing negotiations, or litigation in key markets. Understanding its scope and status enables better strategic planning for drug development and commercialization.
References
- WIPO Patent WO2004011069, Publication date: February 12, 2004.
- Patent family and priority data repositories.
- Patent landscape reports from IQVIA and Clarivate Analytics.
- National patent office databases for legal status updates.
Note: All interpretations are based on standard patent analysis practices and publicly available information.
